GROWTH
Top line accelerating.
+21.2% YoY versus +14.8% prior. 3y CAGR +14.8%.
+21.2%
Incyte Corporation INCY
Healthcare · Market Cap: $21.7B
$98.22▼ 0.77 (0.78%)
Fundamentals as of 2025-12-31
We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $21.7B
Fundamentals as of 2025-12-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
P/E 14.5x — 25% below the 5y median of 19.3x. Forward 13.0x hints at EPS expansion next year.
14.5x2 of 3 legendary models say BUY INCY — but Charlie Munger disagrees.
What would legendary investors pay for INCY?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Yes — Incyte Corporation's 24.9% ROE ranks above the S&P 500 median, and D/E 0.35 stays within healthy bounds.
Financial story
Yes — Incyte Corporation's 24.9% ROE shows strong capital efficiency, and its 0.35 debt-to-equity stays within healthy bounds.
Bottom line: INCY is rated BUY by all 3 legendary models, 39% below avg fair value $160, but earns a B sector grade (71/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
How does INCY compare?
The Question
Buffett, Lynch, and Munger evaluate INCY against their respective frameworks. Per-model fair value and reasoning are in the valuation tab.
INCY's P/E ratio is 15.0x. 5-year P/E history is in the financials tab.
2 of 3 legendary models say BUY. Full breakdown by investor and signal is in the valuation tab.
INCY's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
INCY is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
2 of 3 legendary investor models rate INCY a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
See exactly where INCY ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingINCY sits at #3 in Healthcare with a B grade (71/100).
